<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-037988</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effectiveness of activated factor VII in postoperative bleeding after cardiac surgery with extracorporeal membrane oxygenation</dc:title>
<dc:description xml:lang="en">A 4-year-old girl suffered severe post-operative chesttube drainage bleeding after cardiac transplant surgery requiring extracorporeal membrane oxygenation. Transfusions of platelets and fresh frozen plasma failed to decrease the bleeding. At 2.5 hours a dose of 180 mcg/kg of recombinant activated Factor VII was administered. The hemorrhage decreased from 45 ml/kg/h in the first2.5 hours to 17 ml/kg/h in the next 2.5 hours. The same dose of recombinant activated Factor VII was administered and the hemorrhage suddenly decreased to 1.5 ml/kg/hin the next 2.5 hours, with subsequent disappearance. No adverse events related to activated Factor VII were observed. Recombinant activated Factor VII may be useful in some cases of severe postoperative bleeding in children after cardiac surgery. Randomized controlled studies are needed to confirm its safety and efficacy, and to evaluate the most suitable dose</dc:description>
<dc:creator>López Herce Cid, J</dc:creator>
<dc:creator>Zunzunegui Martínez, J. L</dc:creator>
<dc:creator>Arriola Pereda, G</dc:creator>
<dc:creator>Brandstrup Azuero, K. B</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Una niña de 4 años presentó hemorragia grave por los drenajes torácicos tras cirugía de trasplante cardíaco y oxigenación de membrana extracorpórea (ECMO) a pesar de tratamiento con repetidas transfusiones de plaquetas y plasma fresco congelado. A las 2,5 h de postoperatorio se administró factor VII activado recombinante (FVIIaR)180 g/kg, disminuyendo rápidamente el sangrado de45 a 17 ml/kg/h en las 2,5 h siguientes. Tras una segunda dosis de 180 mg/kg de FVIIaR la hemorragia disminuyó bruscamente a 1,5 ml/kg/h en las siguientes 2,5 h, con desaparición posterior. No se observaron efectos secundarios atribuibles al FVIIa. El FVIIaR puede ser útil en algunos casos de hemorragia grave en el postoperatorio de cirugía cardíaca en niños. Son necesarios estudios comparativos que valoren su eficacia, seguridad y determinen cuál es la dosis más adecuada</dc:description>
<dc:source>An Pediatr (Barc);62(5): 471-474, mayo 2005. ilus, tab</dc:source>
<dc:identifier>ibc-037988</dc:identifier>
<dc:title xml:lang="es">Eficacia del factor VII activado en la hemorragia poscirugía cardíaca y oxigenación con membrana extracorpórea</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d23632^s22045</dc:subject>
<dc:subject>^d32645^s22057</dc:subject>
<dc:subject>^d32645^s22067</dc:subject>
<dc:subject>^d6500</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22431</dc:subject>
<dc:subject>^d24643^s22000</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d24643^s22073</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:type>article</dc:type>
<dc:date>200505</dc:date>
</metadata>
</record>
</ibecs-document>
